**FOI Ref: 6203**

**Category(ies): Clinical - Drugs**

**Subject: Intra-Vitreal Injections or Implants**

**Date Received: 25/01/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am analysing the usage of **intra-vitreal injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions: | |
| 1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreal injections or implants) for each of the following eye conditions:   * Wet Age-Related Macular Degeneration (wAMD) * Diabetic Macular Oedema (DMO) * Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO) * Any other eye condition | 478  184  188  2 |
| 2. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2021:   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Fluocinolone acetonide * Ranibizumab | 764  0  68  12  1  1057 |
| 3. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2021. | |  |  |  |  | | --- | --- | --- | --- | | **Number of Injections/Implants: Sep to Dec 2021** | | | | |  |  |  |  | |  | **Eye Conditions** | | | | **Treatment** | wAMD | DMO | RVO | | Aflibercept | 414 | 194 | 156 | | Bevacizumab | 0 | 0 | 0 | | Brolucizumab | 68 | 0 | 0 | | Dexamethasone | 0 | 2 | 8 | | Fluocinolone acetonide | 0 | 1 | 0 | | Ranibizumab | 564 | 289 | 204 | |